Published in Clin Chem on December 18, 2008
Effects of human C-reactive protein on pathogenesis of features of the metabolic syndrome. Hypertension (2011) 1.71
Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease--a perspective. Drug Des Devel Ther (2010) 1.06
Endothelial dysfunction and preeclampsia: role of oxidative stress. Front Physiol (2014) 1.04
C-reactive protein impairs the endothelial glycocalyx resulting in endothelial dysfunction. Cardiovasc Res (2009) 0.92
Jupiter to Earth: CRP promotes atherothrombosis. Metab Syndr Relat Disord (2009) 0.81
Tamoxifen alters the plasma concentration of molecules associated with cardiovascular risk in women with breast cancer undergoing chemotherapy. Oncologist (2012) 0.79
A Common Profile of Disordered Angiogenic Factor Production and the Exacerbation of Inflammation in Early Preeclampsia, Late Preeclampsia, and Intrauterine Growth Restriction. PLoS One (2016) 0.77
C-Reactive Protein: An In-Depth Look into Structure, Function, and Regulation. Int Sch Res Notices (2014) 0.75
Evaluation of cardiovascular risk in stages of gout by a complex multimodal ultrasonography. Rheumatol Int (2016) 0.75
Lipid and C-reactive protein levels, cardiovascular disease risk factors and simvastatin treatment in Brazilian individuals. Inflammation (2010) 0.75
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Targeting C-reactive protein for the treatment of cardiovascular disease. Nature (2006) 4.07
A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation (2002) 2.76
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
FcgammaRIIB mediates C-reactive protein inhibition of endothelial NO synthase. Circ Res (2005) 1.97
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. J Lipid Res (2008) 1.33
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation (2007) 1.19
Impaired endothelial function in C-reactive protein overexpressing mice. Atherosclerosis (2008) 1.09
Adeno-associated virus-mediated human C-reactive protein gene delivery causes endothelial dysfunction and hypertension in rats. Clin Chem (2008) 1.09
Native C-reactive protein induces endothelial dysfunction in ApoE-/- mice: implications for iNOS and reactive oxygen species. Atherosclerosis (2007) 0.96
Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest (2006) 4.51
Clinical and pathophysiological implications of a bicuspid aortic valve. Circulation (2002) 3.98
Adipokines: molecular links between obesity and atheroslcerosis. Am J Physiol Heart Circ Physiol (2005) 3.15
Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab (2007) 2.84
Vitamins E and C are safe across a broad range of intakes. Am J Clin Nutr (2005) 2.72
Increased monocytic activity and biomarkers of inflammation in patients with type 1 diabetes. Diabetes (2006) 2.65
Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation (2002) 2.50
New markers of inflammation and endothelial cell activation: Part I. Circulation (2003) 2.43
Increased toll-like receptor (TLR) activation and TLR ligands in recently diagnosed type 2 diabetic subjects. Diabetes Care (2010) 2.39
Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop. Arterioscler Thromb Vasc Biol (2008) 2.29
High glucose induces toll-like receptor expression in human monocytes: mechanism of activation. Diabetes (2008) 2.23
C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation (2003) 2.16
C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation (2003) 2.09
Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation (2006) 2.06
Angiotensin receptor blockers and myocardial infarction. BMJ (2004) 2.02
C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension (2004) 1.99
Vascular matrix remodeling in patients with bicuspid aortic valve malformations: implications for aortic dilatation. J Thorac Cardiovasc Surg (2003) 1.96
Endothelial progenitor cells: new hope for a broken heart. Circulation (2003) 1.93
Knockout of toll-like receptor-4 attenuates the pro-inflammatory state of diabetes. Cytokine (2011) 1.91
Retracted Alpha-lipoic acid supplementation and diabetes. Nutr Rev (2008) 1.86
High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab (2007) 1.85
Evidence of increased inflammation and microcirculatory abnormalities in patients with type 1 diabetes and their role in microvascular complications. Diabetes (2007) 1.84
Adiponectin deficiency promotes endothelial activation and profoundly exacerbates sepsis-related mortality. Am J Physiol Endocrinol Metab (2008) 1.79
South Asians and cardiovascular risk: what clinicians should know. Circulation (2006) 1.74
Enalapril increases ischemia-induced endothelial progenitor cell mobilization through manipulation of the CD26 system. J Mol Cell Cardiol (2006) 1.69
Validation of an immunoassay for soluble Klotho protein: decreased levels in diabetes and increased levels in chronic kidney disease. Am J Clin Pathol (2012) 1.67
C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation (2004) 1.65
Microvascular function predicts cardiovascular events in primary prevention: long-term results from the Firefighters and Their Endothelium (FATE) study. Circulation (2011) 1.58
Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem (2009) 1.57
Perceptions of Canadian primary care physicians towards cardiovascular risk assessment and lipid management. Can J Cardiol (2012) 1.56
Liver fibrosis and hepatocyte apoptosis are attenuated by GKT137831, a novel NOX4/NOX1 inhibitor in vivo. Free Radic Biol Med (2012) 1.54
Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol (2013) 1.54
Development of an in vitro screening assay to test the antiinflammatory properties of dietary supplements and pharmacologic agents. Clin Chem (2005) 1.53
Glitazones and heart failure: critical appraisal for the clinician. Circulation (2003) 1.53
Canadian Cardiovascular Society Consensus Conference: peripheral arterial disease - executive summary. Can J Cardiol (2005) 1.53
Relationship between carotid artery intima-media thickness and brachial artery flow-mediated dilation in middle-aged healthy men. J Am Coll Cardiol (2005) 1.53
Oxidative stress and atherosclerosis. Pathophysiology (2006) 1.52
Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol (2008) 1.51
Plasma antioxidant capacity in response to diets high in soy or animal protein with or without isoflavones. Am J Clin Nutr (2005) 1.51
Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and -{beta}. Diabetes (2005) 1.50
New developments in the treatment of hypoplastic left heart syndrome. Pediatrics (2007) 1.49
The evolving role of C-reactive protein in atherothrombosis. Clin Chem (2008) 1.48
Mechanical stretch regimen enhances the formation of bioengineered autologous cardiac muscle grafts. Circulation (2002) 1.45
Free fatty acids in the presence of high glucose amplify monocyte inflammation via Toll-like receptors. Am J Physiol Endocrinol Metab (2010) 1.45
Contrasting effects of oral versus transdermal estrogen on serum amyloid A (SAA) and high-density lipoprotein-SAA in postmenopausal women. Arterioscler Thromb Vasc Biol (2004) 1.43
Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab (2006) 1.42
Suboptimal use of statin therapy in elderly patients with atherosclerosis: a population-based study. J Vasc Surg (2008) 1.42
Human C-reactive protein and the metabolic syndrome. Curr Opin Lipidol (2009) 1.40
MicroRNA-145 targeted therapy reduces atherosclerosis. Circulation (2012) 1.39
Quantification of daratumumab in the serum protein electrophoresis. Clin Chem Lab Med (2016) 1.39
CD11c/CD18 expression is upregulated on blood monocytes during hypertriglyceridemia and enhances adhesion to vascular cell adhesion molecule-1. Arterioscler Thromb Vasc Biol (2010) 1.37
TIMP-3 deficiency leads to dilated cardiomyopathy. Circulation (2004) 1.36
Knockout of toll-like receptor-2 attenuates both the proinflammatory state of diabetes and incipient diabetic nephropathy. Arterioscler Thromb Vasc Biol (2011) 1.34
Adiponectin primes human monocytes into alternative anti-inflammatory M2 macrophages. Am J Physiol Heart Circ Physiol (2010) 1.34
C-reactive protein decreases prostacyclin release from human aortic endothelial cells. Circulation (2003) 1.34
Rosuvastatin, identified from a zebrafish chemical genetic screen for antiangiogenic compounds, suppresses the growth of prostate cancer. Eur Urol (2010) 1.32
Dietary factors that promote or retard inflammation. Arterioscler Thromb Vasc Biol (2006) 1.32
Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. Am J Physiol Heart Circ Physiol (2008) 1.32
Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome. Free Radic Biol Med (2007) 1.30
The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res (2006) 1.28
Adiponectin and cardiovascular disease: state of the art? Am J Physiol Heart Circ Physiol (2006) 1.27
Adipose tissue dysfunction in nascent metabolic syndrome. J Obes (2013) 1.26
Cellular basis of endothelial dysfunction in small mesenteric arteries from spontaneously diabetic (db/db -/-) mice: role of decreased tetrahydrobiopterin bioavailability. Br J Pharmacol (2002) 1.26
Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis (2009) 1.26
Adipose tissue dysregulation in patients with metabolic syndrome. J Clin Endocrinol Metab (2011) 1.25
C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol (2007) 1.25
Female rats are protected against fructose-induced changes in metabolism and blood pressure. Am J Physiol Heart Circ Physiol (2002) 1.24
Alpha-tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-alpha. Diabetes (2002) 1.24
Stem cell factor deficiency is vasculoprotective: unraveling a new therapeutic potential of imatinib mesylate. Circ Res (2006) 1.24
Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol (2011) 1.24
Binding and internalization of C-reactive protein by Fcgamma receptors on human aortic endothelial cells mediates biological effects. Arterioscler Thromb Vasc Biol (2005) 1.23
Comparison of the antioxidant effects of Concord grape juice flavonoids alpha-tocopherol on markers of oxidative stress in healthy adults. Am J Clin Nutr (2002) 1.23
Adropin is a novel regulator of endothelial function. Circulation (2010) 1.21
C-reactive protein stimulates superoxide anion release and tissue factor activity in vivo. Atherosclerosis (2008) 1.21
C-reactive protein decreases interleukin-10 secretion in activated human monocyte-derived macrophages via inhibition of cyclic AMP production. Arterioscler Thromb Vasc Biol (2006) 1.21
Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. J Clin Endocrinol Metab (2003) 1.19
Reduced nicotinamide adenine dinucleotide phosphate oxidase 2 plays a key role in stellate cell activation and liver fibrogenesis in vivo. Gastroenterology (2010) 1.18
Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant status. Endocrinol Metab Clin North Am (2004) 1.17
Innate immunity genes influence the severity of acute appendicitis. Ann Surg (2004) 1.16
Chronic oral supplementation with sepiapterin prevents endothelial dysfunction and oxidative stress in small mesenteric arteries from diabetic (db/db) mice. Br J Pharmacol (2003) 1.16